Although the molecular mechanism of EMT-related EGFR-TKI resistance is largely unknown, reversed EMT by an ectopic expression of E-cadherin or a long-term withdrawal of EGFR-TKI sensitizes the non-T790M EGFR-TKI-resistant NSCLC cell lines to the EGFR-TKI treatment [102,103]. Here, CDH1 is linked to non-small cell lung carcinoma.